In the Specification:

Please replace the paragraph starting on page 15 at line 26 with the following amended paragraph:

> Initially, we synthesized an oligonucleotide labeled by an azido group at the 5′ end as shown in Fig. 1. 5-Azidovaleric acid was synthesized according to the literature (18) and activated as N-succinimidyl ester "1" (87%). The oligonucleotide 5′-amino-GTT TTC CCA GTC ACG ACG-3′ (SEQ ID NO:1) (M13 -40 universal forward sequencing primer) was reacted with excess succinimidyl 5-azidovalerate "1" to produce the azido-labeled DNA "2" (see Fig. 1). After size-exclusion chromatography to remove excess starting material 1 and desalting with an oligonucleotide purification cartridge, the product was analyzed with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Figure 2 shows the MALDI-TOF MS spectrum of the isolated product, with a single major peak at 5757 Da that matched very well with the calculated value of 5758 Da for the azido-DNA 2. This indicates that the starting material amino-DNA was quantitatively converted to the azido-DNA 2 (coupling yield ~ 96%).

Please replace the paragraph starting on page 6 at line 4 with the following amended paragraph:

> Figure 1: Scheme for synthesizing an oligonucleotide (SEQ ID NO:1) labeled by an azido group at the 5′ end.

Please replace the paragraph starting on page 6 at line 9 with the following amended paragraph:

Figure 3: Scheme showing 1,3-dipolar cycloaddition between alkynyl-FAM and azido-labeled DNA (all SEQ ID NO:1).

Please replace the paragraph starting on page 6 at line 13 with the following amended paragraph:

Figure 5: Electropherogram of the DNA sequencing fragments (top: SEQ ID NO:2; bottom: SEQ ID NO:3) generated with structures 4 and 5.

Please replace the paragraph starting on page 6 at line 24 with the following amended paragraph:

Figure 11: Immobilization of DNA (SEQ ID NO:4) on a glass surface in the presence of Cu(I) Catalyst.

Sequence Listing

Please replace the current Sequence Listing with the paper copy Sequence listing attached hereto as **Exhibit B**.